We believe our two proprietary technology platforms solve major hurdles in RNA medicine development such as delivery challenges, limited potency, and narrow therapeutic index.
LUNAR® Mechanism of Delivery Video
Our first platform is a novel lipid-mediated delivery system called Lipid-enabled and Unlocked
Nucleomonomer Agent modified RNA (LUNAR®). LUNAR is a multi-component drug delivery system that is versatile and
with our library of over 150 proprietary lipids, diverse. Our preclinical studies have shown that formulations can
be customized for the indication and target cell type of interest. We have also demonstrated that our formulation
process is scalable and reproducible.
LUNAR®-mediated delivery of RNA into cells
LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.
Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.
With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.
Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.
May 21, 2020
Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics
May 8, 2020
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
May 7, 2020
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update